- Home
- EDRY vs CRBU Comparison
EDRY vs CRBU Comparison
Compare EDRY & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | CRBU |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 138.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDRY | CRBU |
|---|---|---|
| Price | $43.71 | $0.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $45.33 | $5.75 |
| AVG Volume (30 Days) | 99.9K | ★ 5.0M |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.95 | $145.34 |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.09 | $0.44 |
| 52 Week High | $73.07 | $3.53 |
Technical Indicators
Market Signals| Indicator | EDRY | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 22.79 |
| Support Level | $42.00 | N/A |
| Resistance Level | $53.93 | $0.58 |
| Average True Range (ATR) | 3.47 | 0.04 |
| MACD | -0.48 | 0.02 |
| Stochastic Oscillator | 13.57 | 5.57 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.